BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2503-12. [PMID: 32914535 DOI: 10.1111/jth.15009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sakai K, Fujimura Y, Miyata T, Isonishi A, Kokame K, Matsumoto M. Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort. Br J Haematol 2021;194:444-52. [PMID: 34046888 DOI: 10.1111/bjh.17560] [Reference Citation Analysis]
2 Lu R, Sui J, Zheng XL. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura. Blood Adv 2020;4:5378-88. [PMID: 33141886 DOI: 10.1182/bloodadvances.2020003065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Schwaegermann MK, Hobohm L, Rausch J, Reuter M, Griemert TF, Sivanathan V, Falter T, Sprinzl MF, Lackner KJ, Galle PR, Konstantinides S, Theobald M, von Auer C. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report. Hamostaseologie 2021. [PMID: 34327693 DOI: 10.1055/a-1497-1054] [Reference Citation Analysis]
4 Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med 2021;10:536. [PMID: 33540569 DOI: 10.3390/jcm10030536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
5 Lemiale V, Valade S, Mariotte E. Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions. Ther Clin Risk Manag 2021;17:577-87. [PMID: 34113115 DOI: 10.2147/TCRM.S205632] [Reference Citation Analysis]
6 Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;14:707-19. [PMID: 34275393 DOI: 10.1080/17474086.2021.1956898] [Reference Citation Analysis]
7 Elverdi T, Özer Çerme MD, Aydın T, Eşkazan AE. Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert Rev Clin Pharmacol 2021;:1-6. [PMID: 34130583 DOI: 10.1080/17512433.2021.1944102] [Reference Citation Analysis]
8 Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2496-502. [PMID: 32914526 DOI: 10.1111/jth.15010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 13.5] [Reference Citation Analysis]
9 Picod A, Veyradier A, Coppo P. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab? J Thromb Haemost 2021;19:58-67. [PMID: 33236389 DOI: 10.1111/jth.15194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]